After 2 delays, Zogenix nabs FDA approval for epilepsy drug, sets price at 3X its GW Pharma competitor
Fourteen months after refusing to file Zogenix’s first application, the FDA has approved the California biotech’s lead drug for a rare form of epilepsy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
